Home / Market News / $PLSE
benzinga Corporate Catalyst Impact 55/100 ● positive

Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60

Oct 13, 2026, 1:34 PM UTC · Primary ticker $PLSE

Oppenheimer analyst Suraj Kalia has reiterated an 'Outperform' rating on Pulse Biosciences and significantly increased its price target from $35 to $60. This analyst action suggests a strong positive outlook for the company's future performance and could lead to increased investor interest.

Oppenheimer analyst Suraj Kalia has maintained an 'Outperform' rating on Pulse Biosciences (PLSE) and raised the price target from $35 to $60. This is a significant positive signal for PLSE as it indicates a strong belief in the company's growth prospects and valuation by a reputable analyst. This action could lead to increased investor confidence and potentially drive up the stock price in the short term. For traders, this presents an opportunity for a positive momentum play, though the long-term implications will depend on the company's actual performance and execution against the analyst's expectations. The key risk is that the market may not fully agree with the analyst's valuation, or the company may fail to meet future milestones.

$PLSE positive Analyst price target increase and 'Outperform' rating maintained
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.